Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

ImmunityBio Announces FDA Approval of ANKTIVA®,

ImmunityBio, Inc. an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with...

Moleculin's AML treatment gets EMA's Orphan Drug Designation

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, announced that the European Medicines Agency has...

Beckman Coulter's DxI 9000 Immunoassay Analyzer

Beckman Coulter Diagnostics, a leader in clinical diagnostics, announced ahead of the congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), that it has extended the menu of DxI 9000 Immunoassay...

Algiax Pharmaceuticals expands AP-325 study in chronic neuropathic pain, adds 12 sites in Belgium and France

Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain. Based on last year's positive mid-enrollment interim analysis and confirmed...

Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced three poster presentations at the 2024...

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701....

Trailblazing 3D human liver models yield accurate MASH phenotype

Viscient Biosciences ("Viscient") announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medical research institute, and Salk Institute, have published the first demonstration of a...

Editorial Guidelines | Pharmaceutical-Era.com

Editorial Guidelines At Pharmaceutical-Era.com, we strive to maintain the highest standards of quality and integrity in our editorial content. Our guidelines are designed to ensure that all articles, press releases, and other submissions are...

FAQs

Frequently Asked Questions (FAQs) What are the genuine benefits of using Pharmaceutical-Era.com for press release distribution or promotion? Pharmaceutical-Era.com offers unparalleled visibility to your press releases within the pharmaceutical...

Terms of Use | Pharmaceutical-Era.com - Understand Our Terms and Conditions

Terms Of Use — Terms & Conditions Welcome to Pharmaceutical-Era (referred to as "Pharmaceutical-Era," "we," "us," or "our"). By accessing or using our website (www.pharmaceutical-era.com), you agree to comply with and be bound by the following...

Privacy Policy | Pharmaceutical-Era.com - Protecting Your Information

Privacy Policy At Pharmaceutical-Era, we are committed to protecting your privacy. This Privacy Policy outlines how we collect, use, and disclose personal information when you use our website (www.pharmaceutical-era.com). Information We Collect:...